English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Identification and directed development of non-organic catalysts with apparent pan-enzymatic mimicry into nanozymes for efficient prodrug conversion

MPS-Authors
/persons/resource/persons188005

Savateev,  Aleksandr
Aleksandr Savateev, Kolloidchemie, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Walther, R., Winther, A. K., Fruergaard, A. S., van den Akker, W., Sørensen, L., Nielsen, S. M., et al. (2019). Identification and directed development of non-organic catalysts with apparent pan-enzymatic mimicry into nanozymes for efficient prodrug conversion. Angewandte Chemie International Edition, 58(1), 278-282. doi:10.1002/anie.201812668.


Cite as: https://hdl.handle.net/21.11116/0000-0002-7A8F-5
Abstract
Nanozymes, nanoparticles that mimic the natural activity of enzymes, are intriguing academically and are important in the context of Origin of Life. However, current nanozymes offer mimicry to a narrow range of mammalian enzymes, near-exclusively performing redox reactions. In this work, we present an unexpected discovery of non-proteinaceous enzymes based on metals, metal oxides, 1D/2D-materials, and non-metallic nanomaterials. Specific novelty of our findings lies in the identification of nanozymes with apparent mimicry of diverse mammalian enzymes, including unique pan-glycosidases. Further novelty lies in the identification of the substrate scope for the lead candidates, specifically in the context of bioconversion of glucuronides, that is, human metabolites and privileged prodrugs in the field of enzyme-prodrug therapies. Lastly, nanozymes are employed for conversion of glucuronide prodrugs into marketed anti-inflammatory and antibacterial agents, as well as ?nanozyme prodrug therapy? to mediate antibacterial measures.